Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hematological Improvement of Patients With Active Rheumatoid Arthritis by Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Pubmed



Ahmadi H1 ; Jamshidi AR2 ; Mahmoudi M2 ; Gharibdoost F2 ; Vojdanian M2 ; Fattahi MJ1, 3 ; Rastkari N4 ; Aghazadeh Z1 ; Mirshafiey A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran
  2. 2. Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Institute for Cancer Research (ICR), School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Center for Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Allergy# Asthma and Immunology Published:2017


Abstract

The aim of this study was to investigate the effect of β-D-mannuronic acid (M2000) on hematological parameters in patients with active rheumatoid arthritis. This study was conducted on 25 patients with active rheumatoid arthritis (RA) (identifier: IRCT2014011213739N2). M2000 was administered orally for anemic and non-anemic RA patients at a dose of 500 mg twice daily for 12 weeks. The patients were permitted to continue the conventional treatments excluding NSAIDs. Blood samples were collected at baseline, 4 and 12 weeks after drug administration and were tested for hematological parameters. Moreover, serum levels of TNF-α and IL-6 were analysed before and after M2000 therapy compared to healthy controls using enzyme linked immunosorbent assay method. We found a significant increase in the count of red blood cells and also hemoglobin (Hb) concentration (0.9 g/dL) in anemic patients after 12 weeks of M2000 therapy (p<0.02 and p<0.01, respectively). Furthermore, our results showed an improvement in Hb level (0.45 g/dL) even in non-anemic patients who were treated by M2000 (p<0.04). The leukocytosis in RA patients, significantly decreased in both anemic and non-anemic patients after 12 weeks of M2000 therapy (p<0.02 and p<0.03, respectively). The percent of neutrophils significantly increased in anemic patients (p<0.01) while in non-anemic patients it significantly decreased after 12 weeks of M2000 therapy (p<0.01). The serum levels of IL-6 and TNF-α significantly decreased after 12 weeks of M2000 therapy (p<0.01 and p<0.04, respectively). M2000 improves hematological parameters in RA patients by its potent inhibitory effect on serum levels of TNF-α and IL-6. © Copyright Autumn 2017, Iran J Allergy Asthma Immunol. All rights reserved.
Related Docs
View other Related Docs
1. The Role of Β-D-Mannuronic Acid, As a New Non-Steroidal Anti-Inflammatory Drug on Expression of Mir-146A, Irak1, Traf6, Nf-Κb and Pro-Inflammatory Cytokines Following a Clinical Trial in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
2. A Phase I/Ii Randomized, Controlled, Clinical Trial for Assessment of the Efficacy and Safety of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2018)
3. The Potent Inhibitory Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Antidsdna Antibodies in Patients With Rheumatoid Arthritis, Current Drug Discovery Technologies (2017)
4. International Multicenter Randomized, Placebo-Controlled Phase Iii Clinical Trial of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2019)
5. Effects of Β-D-Mannuronic Acid, As a Novel Non-Steroidal Anti-Inflammatory Medication Within Immunosuppressive Properties, on Il17, Rorγt, Il4 and Gata3 Gene Expressions in Rheumatoid Arthritis Patients, Drug Design# Development and Therapy (2017)
6. Targeting of Circulating Th17 Cells by Β-D-Mannuronic Acid (M2000) As a Novel Medication in Patients With Rheumatoid Arthritis, Inflammopharmacology (2018)
7. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
8. Effect of Β-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymes’ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property, Current Drug Discovery Technologies (2019)
Experts (# of related papers)
View all Related Experts
Ahmad Reza Jamshidi (9)
Mahdi Mahmoudi (9)
Other Related Docs
9. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property, Endocrine# Metabolic and Immune Disorders - Drug Targets (2018)
10. Cardioprotective Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Gene Expression of Oxldl Scavenger Receptors in the Experimental Diabetic Model, Immunopharmacology and Immunotoxicology (2018)
11. Introduction of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Based on Cox-1/Cox-2 Activity and Gene Expression, Pharmacological Reports (2017)
12. Immunotherapeutic Effects of Β-D Mannuronic Acid on Il-4, Gata3, Il-17 and Rorc Gene Expression in the Pbmc of Patients With Inflammatory Bowel Diseases, Iranian Journal of Allergy# Asthma and Immunology (2018)
13. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
14. A Controlled, Randomized Phase Ii Clinical Trial for Efficacy and Safety Evaluation of Mannuronic Acid in Secondary Progressive Form of Multiple Sclerosis, International Journal of Neuroscience (2022)
15. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)
16. The Effects of Β-D-Mannuronic Acid (M2000), As a Novel Nsaid, on Cox1 and Cox2 Activities and Gene Expression in Ankylosing Spondylitis Patients and the Murine Monocyte/Macrophage, J774 Cell Line, Inflammopharmacology (2018)
17. A Randomized, Controlled, Phase Ii Clinical Trial of Β-D-Mannuronic Acid (M2000) in Pre-Surgical Breast Cancer Patients at Early Stage (T1-T2), Clinical and Experimental Pharmacology and Physiology (2019)
18. Effects of M2000 (D -Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer's Disease, American Journal of Alzheimer's Disease and other Dementias (2017)
19. Oral Administration Effects of Β-D-Mannuronic Acid (M2000) on Th17 and Regulatory T Cells in Patients With Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)
20. Targeting of Crosstalk Between Tumor and Tumor Microenvironment by Β-D Mannuronic Acid (M2000) in Murine Breast Cancer Model, Cancer Medicine (2017)
21. Effects of Mannuronic Acid (M2000) on Gene Expression Profile of Signal Transducer and Activator of Transcription Proteins (Stats) in Rheumatoid Arthritis Patients, Reumatismo (2020)
22. Anti-Diabetic Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Insulin Production, Blood Glucose, and Inflammatory Markers in the Experimental Diabetes Model, Archives of Physiology and Biochemistry (2019)
23. The Effects of Mannuronic Acid on Il-1Β, Il-17A, Stat1, and Stat3 Gene Expressions and Tlr2 and Tlr4 Molecules in Multiple Sclerosis, Journal of Clinical Pharmacology (2022)
24. The Biology of Β-D-Mannuronic Acid (M2000) on Human Dendritic Cell Based on Microrna-155 and Microrna-221, Current Drug Discovery Technologies (2017)
25. Preclinical Assessment of Β - D -Mannuronic Acid (M2000) As a Non-Steroidal Anti-Inflammatory Drug, Immunopharmacology and Immunotoxicology (2015)
26. Influence of Β-D-Mannuronic Acid, As a New Member of Non-Steroidal An-Ti-Inflammatory Drugs Family, on the Expression Pattern of Chemokines and Their Receptors in Rheumatoid Arthritis, Current Drug Discovery Technologies (2021)
27. Immunomodulatory Effects of M2000 (Β-D-Mannuronic Acid) on Tnf-Α, Il-17 and Foxp3 Gene Expression in Patients With Inflammatory Bowel Disease, International Immunopharmacology (2017)
28. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients, Current Drug Discovery Technologies (2020)
29. The Anti-Tumoral Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Treg Cells Frequency and Mmp-2, Mmp-9, Ccl22 and Tgfβ1 Gene Expression in Pre-Surgical Breast Cancer Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
30. M2000 (Β-D-Mannuronic Acid) As a Novel Antagonist for Blocking the Tlr2 and Tlr4 Downstream Signalling Pathway, Scandinavian Journal of Immunology (2017)
31. Preclinical and Pharmacotoxicology Evaluation of Α-L-Guluronic Acid (G2013) As a Non-Steroidal Anti-Inflammatory Drug With Immunomodulatory Property, Immunopharmacology and Immunotoxicology (2017)
32. Anti-Angiogenesis Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Properties Under Experimental Model, Clinical and Experimental Pharmacology and Physiology (2018)
33. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
34. Evaluation of the Efficacy and Safety of Β-D-Mannuronic Acid in Patients With Ankylosing Spondylitis: A 12-Week Randomized, Placebo-Controlled, Phase I/Ii Clinical Trial, International Immunopharmacology (2018)
35. Efficacy of Β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules Nfҡb, Il-8 and Cd49d Using Healthy Donor Pbmc, Current Drug Discovery Technologies (2020)
36. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
37. Anti-Aging Effects of M2000 (Β-D-Mannuronic Acid) As a Novel Immunosuppressive Drug on the Enzymatic and Non-Enzymatic Oxidative Stress Parameters in an Experimental Model, Journal of Basic and Clinical Physiology and Pharmacology (2017)
38. Anti-Tumor Effect of M2000 (Β-D-Mannuronic Acid) on the Expression of Inflammatory Molecules in the Prostate Cancer Cell, Immunopharmacology and Immunotoxicology (2021)
39. Evaluation of the Effect of Mannuronic Acid As a Novel Nsaid With Immunosuppressive Properties on Expression of Socs1, Socs3, Ship1, and Traf6 Genes and Serum Levels of Il-6 and Tnf-Α in Patients With Multiple Sclerosis, Journal of Clinical Pharmacology (2021)
40. Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes, Journal of Clinical Pharmacology (2020)
41. Evaluation of Cell Adhesion Molecules (Lfa-1 and L-Selectin) in Ankylosing Spondylitis Patients After Treatment With ß-D-Mannuronic Acid (M2000), Indian Journal of Medical Research (2023)
42. Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of Β-D-Mannuronic Acid (M2000), Current Drug Discovery Technologies (2021)
43. The Role of M2000 As an Anti-Inflammatory Agent in Toll-Like Receptor 2/Microrna-155 Pathway, Avicenna Journal of Medical Biotechnology (2017)
44. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients, Recent Patents on Inflammation and Allergy Drug Discovery (2020)
45. An in Vitro Assessment for Evaluating the Efficiency of Β-D-Mannuronic Acid (M2000) in Myelodysplastic Syndrome, Journal of Cellular Physiology (2019)
46. Clinical Improvement of Diabetes Mellitus Type 1 by Β-D-Mannuronic Acid (M2000) in a Breast Cancer Patient - As a Case Report, Clinical Diabetology (2019)
47. Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study, Iranian Journal of Allergy# Asthma and Immunology (2022)
48. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)
49. The Safety Property of P-D-Mannuronic Acid (M2000) As a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells, Current Drug Discovery Technologies (2016)
50. The Evaluation of Safety Property and Apoptotic Efficacy of Α-L-Guluronic Acid (G2013), As a Novel Nsaid, Under in Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines, Recent Advances in Inflammation and Allergy Drug Discovery (2021)